Clinical Efficacy of Combined Use of Azilsartan with Indapamide and Azilsartan with Nitrendipine in Patients with Arterial Hypertension

Z. T. Mashkurova, G. Zh. Abdullaeva, G. A. Khamidullaeva, N. Kh Sherbadalova, M. N. Khatamova, Zh. B. Safarov, M. I. Atoeva

International Journal of Biomedicine. 2022;12(3):367-374.
DOI: 10.21103/Article12(3)_OA3
Originally published September 5, 2022


The aim of our study was a comparative evaluation of the effectiveness of the combined use of azilsartan with indapamide, and azilsartan with nitrendipine in achieving antihypertensive and organ-protective effects in patients with arterial hypertension (AH).
Methods and Results: The study included 101 patients aged 30-75 years (mean age of 53,1±11,2 years) with AH Grades 1-2 (ESC/ESH, 2018), who were on outpatient treatment at the Republican Specialized Scientific and Practical Medical Center for Cardiology.
After the screening stage, all patients were discontinued from previous therapy and assigned to the 2 regimes of dual therapy. Group 1 included 50 AH patients treated with azilsartan (Az) and indapamide (Ind); Group 2 included 51 patients treated with Az and nitrendipine (Nit). The average daily dose of Az was 49.3±6.0 mg, Nit - 10.88±4.3 mg, and Ind - 1.69±0.5 mg. The effectiveness of the prescribed therapy was evaluated after 6 months of treatment.
The 6-month dual therapy with Az+Ind and Az+Net is characterized by high antihypertensive efficacy with a significant positive effect on the parameters of diurnal blood pressure (BP) profile in AH patients.           Achieving the target level of BP in both groups provided high organ-protective efficacy, expressed in a significant regression of LV hypertrophy and LV dimensions, a decrease in the carotid intima-media thickness (CMIT) and arterial rigidity. However, the best cardio- and vaso-protective efficacy was noted in Group 1, which was expressed in a more pronounced improvement in the left ventricular diastolic function, a decrease in the CIMT on both sides, and a significant improvement in the parameters of central hemodynamics and arterial stiffness. Dual therapy with Az+Ind and Az+Nit in AH patients was accompanied by a positive effect on the metabolic profile and excellent nephroprotection, with an advantage in the Az+Ind group. A significant decrease in the blood level of LDL-C, TC, and uric acid is characteristic in both groups of patients. A significant decrease in the levels of FBG and TG occurs only in the Az+Ind therapy.

arterial hypertension • arterial stiffness • left ventricular hypertrophy • antihypertensive medication
  1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019 Feb 1;40(5):475. PMID: 30165516.
  2. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990 Apr 7;335(8693):827-38. doi: 10.1016/0140-6736(90)90944-z. PMID: 1969567.
  3. Nedogoda SV. The elasticity of large arteries is a new target of pharmacotherapy. Monograph. Moscow, 2011.[In Russian].
  4. Nedogoda SV, Chalyabi TA, Marchenko IV, Brel UA, Zaremba DV, Kretov MA. [Change in pulse wave velocity in arterial hypertension]. Journal of VolgSMU. 2005-№3 (15).-S. 48-51. [Article in Russian].  
  5. Lopatin YuM, Semenova NV. [Fixed low-dose combinations of antihypertensive drugs - drugs of first choice for the treatment of arterial hypertension]. Atmosphere. Novosti Kardiologii. 2003;(2). [Article in Russian].  
  6. Perry CM. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig. 2012 Sep 1;32(9):621-39. doi: 10.2165/11209600-000000000-00000. PMID: 22877322.
  7. Baker WL, White WB. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother. 2011 Dec;45(12):1506-15. doi: 10.1345/aph.1Q468. Epub 2011 Nov 24. PMID: 22116996.
  8. Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, Handley A, Kupfer S. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul;13(7):467-72. doi: 10.1111/j.1751-7176.2011.00482.x. Epub 2011 Jun 20. PMID: 21762358; PMCID: PMC8108745.
  9. Bönner G, Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, Handley A, Kupfer S. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013 Aug;27(8):479-86. doi: 10.1038/jhh.2013.6. Epub 2013 Mar 21. PMID: 23514842; PMCID: PMC3715765.
  10. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012 May;35(5):552-8. doi: 10.1038/hr.2012.8. Epub 2012 Jan 26. PMID: 22278628; PMCID: PMC3348575.
  11. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar;57(3):413-20. doi: 10.1161/HYPERTENSIONAHA.110.163402. Epub 2011 Jan 31. PMID: 21282560.
  12. Akishita M, Yamada H, Dzau VJ, Horiuchi M. Increased vasoconstrictor response of the mouse lacking angiotensin II type 2 receptor. Biochem Biophys Res Commun. 1999 Aug 2;261(2):345-9. doi: 10.1006/bbrc.1999.1027. PMID: 10425188.
  13. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999 Feb;33(2):613-21. doi: 10.1161/01.hyp.33.2.613. PMID: 10024316.
  14. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. PMID: 11937178.
  15. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004 Jun 19;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9. PMID: 15207952.
  16. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, Magnani B, Zanchetti A; CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002 Nov;20(11):2293-300. doi: 10.1097/00004872-200211000-00030. PMID: 12409969.
  17. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension. 1997 Jul;30(1 Pt 1):140-5. doi: 10.1161/01.hyp.30.1.140. PMID: 9231834.
  18. Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008 Oct;23(10):3174-83. doi: 10.1093/ndt/gfn230. Epub 2008 May 1. PMID: 18450829.
  19. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999 Mar 4;340(9):677-84. doi: 10.1056/NEJM199903043400902. PMID: 10053176.
  20. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 Oct 24;352(9137):1347-51. doi: 10.1016/s0140-6736(98)03086-4. PMID: 9802273.
  21. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998 Dec;16(12 Pt 1):1823-9. doi: 10.1097/00004872-199816120-00016. PMID: 9869017.
  22. Syrov AV. Treatment of systolic arterial hypertension in the elderly: the role of the new calcium channel blocker nitrendipine. Consilium Medicum. 2017;19(12):54–58.

Download Article
Received June 16, 2022.
Accepted August 3, 2022.
©2022 International Medical Research and Development Corporation.